A patient with atopic dermatitis with poor disease control and conjunctivitis during dupilumab treatment who was successfully switched to baricitinib

Key Points

• The study aims to address a case of atopic dermatitis with poor control and conjunctivitis during dupilumab treatment, exploring a treatment switch to baricitinib.
• Monitoring of atopic dermatitis progression and treatment response with dupilumab and baricitinib.
• Assessment through clinical scoring, specifically the EASI score.
• Use of histamine H1 receptor antagonists and cyclosporine eye drops for conjunctivitis.
• Dupilumab initially improved eczema and pruritus, but conjunctivitis developed after 14 weeks.
• After switching to baricitinib, significant improvement in both conjunctivitis and atopic dermatitis was observed.
• The case suggests that baricitinib may be effective for patients with dupilumab-associated conjunctivitis and worsening dermatitis.